EY Clinical Trial Fast Lane

We are actively seeking to expand our services in other regions beyond US clinical trial sites. If these services are of interest, please reach out to our team to learn more.

Clinical trial activation requires extensive, cross-functional collaboration across the site. Our unique concierge team brings deep knowledge of how sites operate to navigate these complexities, and it provides hands-on support to site personnel to help them deliver significantly accelerated startup timelines. 

In the absence of a true industry standard for calculating clinical trial activation timelines, we generally follow the National Cancer Institute methodology such that the start date is the date of submission to the protocol review and monitoring committee (or, for non-oncology trials, an equivalent feasibility committee), and the end date is the date of site activation. We align with you on how EY Clinical Trial Fast Lane timelines will be calculated and which activities our team will support.

Our preferred model is to develop a performance-based fee system where the cost to implement EY Clinical Trial Fast Lane services is tied directly to how successful we are at accelerating site activation.

Please feel free to reach out for specific details.

We are piloting several solutions to support the acceleration of patient recruitment and enrollment. If these services are of interest, please reach out to our team to learn more.

Our team’s extensive experience across the R&D ecosystem informs our understanding of how clinical trial sponsors and sites work today, including collaboration with other key players in the clinical trial startup process (e.g., commercial IRBs, CROs). We bring deep knowledge of clinical trial site operations to predict and proactively mitigate against common causes of activation delay.